

1 **Rapid SARS-CoV-2 antigen detection by immunofluorescence – a new tool to detect**
2 **infectivity**

3

4 Lorena Porte^{1,*}, Paulette Legarraga¹, Mirentxu Iruetagoiena¹, Valeska Vollrath¹, Gabriel
5 Pizarro¹, José M. Munita^{2,3,4}, Rafael Araos^{2,3,4}, Thomas Weitzel^{1,3,*}

6

7 ¹ Laboratorio Clínico, Clínica Alemana, Universidad del Desarrollo, Santiago, Chile

8 ² Servicio de Infectología, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana,
9 Universidad del Desarrollo, Santiago, Chile

10 ³ Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina Clínica Alemana,
11 Universidad del Desarrollo, Santiago, Chile

12 ⁴ Millennium Initiative for Collaborative Research on Bacterial Resistance (MICROB-R),
13 Santiago, Chile

14

15 *Correspondence: L. Porte (lporte@alemana.cl) and T. Weitzel (thomas.weitzel@gmail.com)

16

17 **Abstract**

18 The evaluated SARS-CoV-2 antigen rapid fluorescence immunoassays reliably identified
19 patients within the first 5 days of symptom onset, when respiratory secretions carried high viral
20 loads. This high performance suggests that these tests might play an important role for future
21 PCR-independent strategies to detect early or infective cases.

22

23 **Key words:** SARS-CoV-2; Covid-19; Diagnosis; Rapid diagnostic test; Antigen detection

24 **Introduction**

25 Since its emergence in 2019, the SARS-CoV-2 pandemic has resulted in over 30 million
26 confirmed cases and almost 1 million deaths worldwide, as of September 2020
27 (<https://covid19.who.int>). Early detection of cases by highly sensitive and specific real-time
28 reverse-transcription polymerase chain reaction (RT-PCR) is the currently recommended
29 diagnostic strategy [1]. However, the high cost of RT-PCR, shortage of reagents, and need for
30 trained personnel have limited the testing capacities of laboratories to provide results in a timely
31 manner [2]. Thus, alternative diagnostic tools allowing the fast testing of large numbers of
32 samples are of high priority [3]. In addition, new aspects of SARS-CoV-2 testing include the
33 ability to evaluate infectivity to help tailor control measures of known or suspected Covid-19
34 cases [4].

35 Rapid antigen detection tests (Ag-RDT) using immunochromatographic tests (ICT) or
36 fluorescent immunoassays (FIA) have recently become available; many of which are CE-IVD
37 licensed and some have received FDA emergency use authorization (EUA) [5]. As previously
38 suggested, FIAs are highly specific and can reach remarkably high sensitivities, if applied in
39 samples from early phases of infection or with high viral loads [6,7]. Here we present the
40 performance of two novel FIA automated antigen detection systems in samples from Covid-19
41 patients presenting within 5 days of symptom onset.

42

43 **Material and methods**

44 Samples derived from patients attending Clínica Alemana in Santiago, Chile, for Covid-
45 19 testing. Specimens consisted of naso-oropharyngeal flocked swabs obtained by trained
46 personnel and placed in universal transport media (UTM-RT[®] System, Copan Diagnostics,

47 Murrieta, CA, USA). Samples were examined for SARS-CoV-2 RNA by RT-PCR assay
48 (COVID-19 Genesig[®], Primerdesign Ltd., Chander's Ford, UK). Samples exhibiting exponential
49 amplification curves and cycle thresholds (Ct) values ≤ 40 were considered positive.

50 RT-PCR characterized UTM samples were aliquoted and kept at -80° C until analysis by
51 the two FIA kits, "SOFIA SARS Antigen FIA" (Quidel Corporation, San Diego, CA, USA) and
52 "STANDARD[®] F COVID-19 Ag FIA" (SD Biosensor Inc., Gyeonggi-do, Republic of Korea).
53 Both tests detect SARS-CoV-2 nucleocapsid protein by lateral flow immunofluorescence, which
54 is interpreted by automated analysers (SOFIA 2, Quidel Corporation; F2400, SD Biosensor Inc.).
55 Both kits are CE-IVD labelled; Quidel recently received FDA EUA. Manufacturers state that
56 both tests should be performed using nasopharyngeal swabs collected from symptomatic
57 individuals within 5 days of symptom onset. The use of samples stored in certain brands of
58 transport media (including Copan UTM) is permitted for the SD Biosensor assay; the Quidel test
59 initially also allowed using UTM, but a recent instruction update discourages the use of
60 prediluted samples [8].

61 For the evaluation, 32 RT-PCR positive UTM samples, all collected within the first 5
62 days after symptom onset, and 32 negative specimens were selected. All positive samples were
63 from symptomatic patients, 12 negative samples were from asymptomatic patients screened
64 before surgery. Some of the positive ($n = 27$) and negative samples ($n = 19$) had been used in a
65 previous evaluation [7]. Assays were performed using the same sample aliquot, following
66 manufacturers' instructions, by the same laboratory personnel, who were blinded to RT-PCR
67 results. In brief, specimens were mixed with an extraction reagent, dispensed into the cassette's
68 sample well, and read after incubation by an instrument. All procedures, except the reading, were
69 performed under a BSL2 cabinet. Results were compared to those of RT-PCR as reference

70 method; in case of discordant results, tests were repeated. Demographic and clinical data were
71 obtained from mandatory notification forms and analysed in an anonymized manner. Statistical
72 analysis considered the calculation of sensitivity, specificity, and accuracy using standard
73 formulas, and Wilson score Confidence Interval at 95% (OpenEpi version 3.01). Test
74 performance was evaluated for all samples and for those with high viral loads ($Ct \leq 25$), as
75 previously described [9]. Kits and analysers were provided by manufacturers at reduced costs for
76 evaluation purposes. The study was approved by the institutional review board (Comité Etico
77 Científico, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile)
78 and a waiver of informed consent was granted.

79 80 **Results**

81 The study included a total of 64 samples, 32 were RT-PCR positive and 32 RT-PCR
82 negative. The median age was 39 years (IQR 36.7-57) and 52% were male. Median days from
83 symptom onset to RT-PCR testing of positive and negative cases were 2 (IQR 1-3) and 1 (IQR
84 0.75-4), respectively. Ct values had a median of 17.95 (IQR, 16.4-22.4); 29/32 samples (90.6%)
85 had a $Ct \leq 25$.

86 Both assays demonstrated an overall sensitivity $>90\%$, reaching 100% for samples with
87 high viral loads (Table 1). False negative results were observed with the Quidel and SD
88 Biosensor assays in two and three samples, respectively, which had Cts of 30.89 to 32.57 and
89 were taken on the fourth or fifth day after symptom onset. Specificity was 96.7% for both tests,
90 i.e. both kits displayed a single false positive result, from two distinct symptomatic RT-PCT
91 negative cases. Both assays were user friendly, included ready-to-use reagents and required little
92 hands-on time. Moreover, analysers were easy-to-use, stored the results, and included options for
93 QR coding, printing, and connection to laboratory information systems.

94 **Discussion**

95 At present, RT-PCR is the recommended diagnostic method in patients with
96 suspected SARS-CoV-2 infection [1]. However, material shortages and laboratory capacity
97 limitations, especially during high transmission situations, have caused significant problems and
98 led to the emergence of various new PCR-independent diagnostics [10]. Antigen-based assays
99 are among the most recent developments, but peer-reviewed evaluations of their diagnostic
100 performance are scarce. Hence, their role within the routine diagnostic workup is yet not defined
101 [9,11]. Since antigen detection per se has a lower sensitivity than RT-PCR, it will most likely not
102 replace it [9]. However, the results of this and former studies indicate that antigen detection by
103 immunofluorescence, especially when used with an automated reader, has an excellent
104 sensitivity to detect SARS-CoV-2 in samples with estimated viral loads above $\sim 10^6$ copies/mL
105 (Ct values ≤ 25) [9], which are found in pre-symptomatic (1-3 days before symptom onset) and
106 early symptomatic Covid-19 cases (5-7 days after symptom onset) [9,12-14]. According to recent
107 modelling studies, elevated viral titers are associated to infectivity [15]. This is in accordance
108 with *in vitro* experiments, which showed no viral growth from samples with Cts > 24 or taken > 8
109 days after symptom onset [16,17]. A viral load of 10^6 copies/mL has therefore been suggested as
110 the limit of infectivity for clinical practice [18]. However, until the exact threshold of
111 contagiousness is known, other authors have considered a more conservative approach (1,000
112 copies/mL) [19].

113 For samples with high viral loads both evaluated tests were 100% sensitive. In our panel
114 of positive samples, false negatives only occurred with Cts > 30 , which translates to viral loads
115 $< 10^4$ for the used RT-PCR protocol [20], although this finding has to be confirmed with a larger
116 number of specimens. The high-performance value coincides with recent studies of a similar FIA

117 with automated reading (BioEasy), which demonstrated sensitivities of 100% for samples with
118 Cts \leq 25 [6,7] and of 98% for samples with Cts \leq 30 [21]. In contrast, immunochromatographic
119 SARS-CoV-2 antigen tests demonstrated lower sensitivity values of 74%-85% for samples with
120 Cts \leq 25 [7,22,23].

121 Although additional studies with larger numbers of samples are needed, the excellent
122 performance data of FIA Ag-RDTs suggest their potential use in the following scenarios, when
123 RT-PCR is unavailable or impractical: 1) closed or semi-closed remote communities such as
124 cruise ships or military camps [9], 2) High-risk congregate facilities including schools, care-
125 homes, dormitories, etc., when testing daily or every other day could reduce secondary infections
126 by 100% or 90%, respectively [24], and 3) screening of asymptomatic attendees at potential
127 superspreader events, like conferences, weddings, and sports or cultural events. In the future, due
128 to their high sensitivity to detect infective patients, FIA Ag-RDTs might also play an important
129 role within “test-out” strategies, i.e. the early release of suspected cases from self-isolation or
130 shortening quarantine for proven cases.

131

132 **Funding**

133 This research did not receive any specific grant from funding agencies in the public,
134 commercial, or not-for-profit sectors.

135

136 **CRedit authorship contribution statement**

137 **L. Porte:** Conceptualization, Data curation, Formal analysis, Investigation, Methodology,

138 Project administration, Supervision, Validation, Writing - original draft, Writing - review &

139 editing. **P. Legarraga:** Formal analysis, Supervision, Validation, Writing - review & editing. **M.**

140 **Iruretagoyena:** Formal analysis, Validation, Writing - review & editing. **G. Pizarro:** Data
141 curation, Investigation. **V. Vollrath:** Supervision, Validation, Writing - review & editing. **J.M.**
142 **Munita:** Validation, Writing - review & editing. **R. Araos:** Validation, Writing - review &
143 editing. **T. Weitzel:** Conceptualization, Formal analysis, Methodology, Project administration,
144 Validation, Writing - original draft, Writing - review & editing.

145

146 **Declaration of competing interest**

147 There is no conflict of interest.

148

149 **Table 1.** Performance of two automated SARS-CoV-2 antigen detection assays compared to RT-PCR

Antigen detection test		RT-PCR			Sensitivity				Specificity		Accuracy
Assay	Result	Positive		Neg.	All		High VL ^a		%	CI95%	%
		All	High VL ^a		%	CI95%	%	CI95%			
Sofia SARS	Positive	30	27	1	93.8	79.9-98.3	100	87.5-100	96.9	84.3-99.4	95.3
Antigen FIA	Negative	2	0	31							
Standard F	Positive	29	27	1	90.6	75.8-96.8	100	87.5-100	96.9	84.3-99.4	93.8
COVID-19 Ag FIA	Negative	3	0	31							

150 VL, viral load; CI95%, confidence interval 95%; Neg., negative

151 ^aSamples with Ct ≤25

152

153 **References**

- 154 1. World Health Organization. Diagnostic testing for SARS-CoV-2: Interim guidance.
155 Available at: <https://www.who.int/publications/i/item/diagnostic-testing-for-sars-cov-2>
- 156 2. World Health Organization. Advice on the use of point-of-care immunodiagnostic tests
157 for COVID-19: Scientific brief. Available at: [https://www.who.int/news-](https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19)
158 [room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-](https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19)
159 [for-covid-19](https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19)
- 160 3. European Centre for Disease Prevention and Control. COVID-19 testing strategies and
161 objectives. 15 September 2020. ECDC: Stockholm; 2020.
- 162 4. Rhee C, Kanjilal S, Baker M, Klompas M. Duration of SARS-CoV-2 infectivity: when is
163 it safe to discontinue isolation. 2020; [https://academic.oup.com/cid/advance-](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1249/5896916)
164 [article/doi/10.1093/cid/ciaa1249/5896916](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1249/5896916)
- 165 5. Foundation for Innovative New Diagnostics. SARS-CoV-2 Diagnostic pipeline 2020.
166 Available at: <https://www.finddx.org/covid-19/pipeline/>
- 167 6. Porte L, Legarraga P, Vollrath V et al. Evaluation of a novel antigen-based rapid
168 detection test for the diagnosis of SARS-CoV-2 in respiratory samples. *Int J Infect Dis*
169 2020; 99:328-333. doi: 10.1016/j.ijid.2020.05.098
- 170 7. Weitzel T, Legarraga P, Iruretagoyena M et al. Head-to-head comparison of four
171 antigen-based rapid detection tests for the diagnosis of SARS-CoV-2 in respiratory
172 samples. Preprint doi: 10.1101/2020.05.27.119255
- 173 8. Quidel Sofia SARS Antigen FIA Package Insert. Available at:
174 <https://www.quidel.com/immunoassays/rapid-sars-tests/sofia-sars-antigen-fia>
- 175 9. World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection
176 using rapid immunoassays: Interim guidance.
177 [https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-](https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays)
178 [2infection-using-rapid-immunoassays](https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays)
- 179 10. Cheng MP, Papenburg J, Desjardins M et al. Diagnostic testing for severe acute
180 respiratory syndrome-related coronavirus-2: A narrative review. *Ann Intern Med* 13 April
181 2020; doi:10.7326/M20-1301

- 182 11. Dinnes J, Deeks JJ, Adriano A et al. Rapid, point-of-care antigen and molecular-based
183 tests for diagnosis of SARS-CoV-2 infection. *Cochrane Database of Systematic Reviews*
184 2020, Issue 8. Art. No.: CD013705. DOI: 10.1002/14651858.CD013705.
- 185 12. He X, Lau E, Wu P et al. Temporal dynamics in viral shedding and transmissibility of
186 COVID-19. *Nature Medicine* 2020; 26:1491-1493. doi:10.1038/s41591-020-0869-5
- 187 13. Lee CY, Lin RTP, Renia L, Ng LFP. Serological approaches for COVID-19:
188 Epidemiologic perspective on surveillance and control. *Front Immunol* 2020;11:879.
- 189 14. Zou L, Ruan F, Huang M et al. SARS-CoV-2 viral load in upper respiratory specimens of
190 infected patients. *N Engl J Med* 2020; 382:12
- 191 15. Larremore DB, Wilder B, Lester E et al. Test sensitivity is secondary to frequency and
192 turnaround time for COVID-19 surveillance. Preprint doi: 10.1101/2020.06.22.20136309
- 193 16. Bullard J, Dust K, Funk D et al. Predicting infectious SARS-CoV-2 from diagnostic
194 samples. *Clin Infect Dis* 2020; ciaa638. doi: 10.1093/cid/ciaa638.
- 195 17. Wölfel R, Corman VM, Guggemos W et al. Virological assessment of hospitalized
196 patients with COVID-2019. *Nature* 2020; 581(7809):465-469. doi:10.1038/s41586-020-
197 2196-x.
- 198 18. Drosten C. Coronavirus Update 54 (podcast), 1 Sept 2020. Transcript available at
199 <https://www.ndr.de/nachrichten/info/coronaskript222.pdf> (accessed 16 Sept 2020)
- 200 19. Jacot D, Greub G, Jaton K, Opota O. Viral load of SARS-1 CoV-2 across patients and
201 compared to other respiratory viruses. Preprint doi: 10.1101/2020.07.15.20154518
- 202 20. Scohy A, Anantharajah A, Bodéus M, Kabamba-Mukadi B, Verroken A, Rodriguez-
203 Villalobos H. Low performance of rapid antigen detection test as frontline testing for
204 COVID-19 diagnosis. *J Clin Virol* 2020; doi:10.1016/j.jcv.2020.104455
- 205 21. Diao B, Wen K, Chen J et al. Diagnosis of acute respiratory syndrome coronavirus 2
206 infection by detection of nucleocapsid protein. Preprint
207 doi:10.1101/2020.03.07.20032524v2
- 208 22. Mertens P, De Vos N, Martiny D et al. Development and potential usefulness of the
209 COVID-19 Ag respi-strip diagnostic assay in a pandemic context. *Front. Med.* 2020;
210 7:225. doi: 10.3389/fmed.2020.00225

- 211 23. Lambert-Niclot S, Cuffel A, Le Pape S et al. Evaluation of a rapid diagnostic assay for
212 detection of SARS CoV-2 antigen in nasopharyngeal swab. *J Clin Microbiol* 2020;
213 58(8):e00977-20. doi:10.1128/JCM.00977-20.
- 214 24. Paltiel DA, Zheng A, Walensky RP. Assessment of SARS-CoV-2 screening strategies to
215 permit the safe reopening of college campuses in the United States. *JAMA Netw Open*
216 2020; 3(7):e2016818